Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of benralizumab response in severe asthma using baseline characteristics and 3-month early response
NL-OMON27637Recruiting
- Sponsor
- Frisius MC
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of benralizumab in asthma and severe asthma, sponsored by Frisius MC. Primary endpoints: Benralizumab response at 1 year and Prediction model for benralizumab response. Started May 2020; status: recruiting.
02
Drugs
benralizumab
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on NL-OMON27637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27637.